Pfizer Recognizes Importance of Certification of Physician Investigators - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
Pfizer Recognizes Importance of Certification of Physician Investigators

Source: Company News Release

Pfizer recognized the Certified Physician Investigator designation obtained through the Association of Clinical Research Professionals' (ACRP) Certification Program as an acceptable method for clinical investigators to demonstrate competency in good clinical practice (GCP) for Pfizer-sponsored clinical trials.

The decision recognizes the importance of high-quality training in the tenets of GCP to promote physician investigators' safe and ethical conduct of clinical trials with human subjects. Pfizer has reviewed the ACRP Certification Program and says it will recognize the CPI® designation for investigators who wish to conduct Pfizer-sponsored clinical trials.

The examination taken by qualified physicians wishing to earn the CPI® designation is administered by the Academy of Clinical Research Professionals, an affiliate of ACRP that also oversees the Certified Clinical Research Coordinator (CCRC®) and Certified Clinical Research Associate (CCRA®) Certification Programs. The non-profit ACRP was founded in 1976 to promote integrity and excellence in the field and, since 1992, has been the leading certifier of clinical research professionals with more than 24,000 professionals, including nearly 1,100 CPIs, having earned a designation to date.  

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Company News Release,
Click here